Cost Effectiveness of Tobramycin Versus Azithromycin as First-Line Therapy for Acute Exacerbations Among Patients with Non-Cystic Fibrosis Bronchiectasis
Abstract
Authors
RP Patel LA Clark V Parvathagiri JM Noone CM Blanchette R Howden